Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Among adults with relapsed acute lymphoblastic leukemia, treatment with the anti-CD22 drug conjugate inotuzumab ozogamicin produced a higher rate of complete remission, as well as a higher rate of veno-occlusive disease, than did standard chemotherapy.
An estimated 2650 adults in the United States received a new diagnosis of acute lymphocytic le...
Alternative Titles
Full title
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1814656079
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1814656079
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1509277
